Xeris Biopharma Holdings, Inc. (XERS)
10.68
+0.23
(+2.20%)
USD |
NASDAQ |
Oct 28, 10:39
Xeris Biopharma Holdings Enterprise Value : 1.982B for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 1.982B |
| October 26, 2026 | 1.940B |
| October 23, 2026 | 1.938B |
| October 22, 2026 | 2.053B |
| October 21, 2026 | 2.040B |
| October 20, 2026 | 2.100B |
| October 19, 2026 | 2.069B |
| October 16, 2026 | 1.957B |
| October 15, 2026 | 1.916B |
| October 14, 2026 | 1.864B |
| October 13, 2026 | 1.938B |
| October 12, 2026 | 1.983B |
| October 09, 2026 | 1.987B |
| October 08, 2026 | 1.937B |
| October 07, 2026 | 1.923B |
| October 06, 2026 | 1.916B |
| October 05, 2026 | 1.926B |
| October 02, 2026 | 1.744B |
| October 01, 2026 | 1.773B |
| September 30, 2026 | 1.827B |
| September 29, 2026 | 1.900B |
| September 28, 2026 | 1.874B |
| September 25, 2026 | 1.747B |
| September 24, 2026 | 1.721B |
| September 23, 2026 | 1.671B |
| Date | Value |
|---|---|
| September 22, 2026 | 1.683B |
| September 21, 2026 | 1.695B |
| September 18, 2026 | 1.591B |
| September 17, 2026 | 1.584B |
| September 16, 2026 | 1.518B |
| September 15, 2026 | 1.468B |
| September 14, 2026 | 1.482B |
| September 11, 2026 | 1.461B |
| September 10, 2026 | 1.499B |
| September 09, 2026 | 1.506B |
| September 08, 2026 | 1.640B |
| September 04, 2026 | 1.648B |
| September 03, 2026 | 1.659B |
| September 02, 2026 | 1.657B |
| September 01, 2026 | 1.631B |
| August 31, 2026 | 1.633B |
| August 28, 2026 | 1.640B |
| August 27, 2026 | 1.661B |
| August 26, 2026 | 1.674B |
| August 25, 2026 | 1.685B |
| August 24, 2026 | 1.685B |
| August 21, 2026 | 1.678B |
| August 20, 2026 | 1.661B |
| August 19, 2026 | 1.692B |
| August 18, 2026 | 1.704B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Zevra Therapeutics, Inc. | 376.61M |
| ANI Pharmaceuticals, Inc. | 1.870B |
| Corcept Therapeutics, Inc. | 9.154B |
| Veru, Inc. | 15.77M |
| Johnson & Johnson | 674.29B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -31.10M |
| Revenue (Quarterly) | 92.10M |
| Total Expenses (Quarterly) | 123.20M |
| EPS Diluted (Quarterly) | -0.18 |
| Gross Profit Margin (Quarterly) | 83.47% |
| Profit Margin (Quarterly) | -33.77% |
| Earnings Yield | -0.96% |
| Operating Earnings Yield | 1.94% |
| Normalized Earnings Yield | 0.2088 |